Court Rejects AbbVie Patent Suits, Boosting FTC Pay-for-Delay Claims

Generic Line
A A
A federal judge in Pennsylvania threw out AbbVie’s patent suits against generic competitors, strengthening the Federal Trade Commission’s pay-for-delay case against the drugmaker.

To View This Article:

Login

Subscribe To Generic Line